Bispecific Antibody Stabilization via Cyclodextrin Mediator
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein pharmaceuticals face significant challenges due to their marginal stability and susceptibility to degradation, particularly protein aggregation, which affects biological activity, product yield, and can lead to adverse immunogenic reactions, especially during refolding, purification, sterilization, shipping, and storage processes.
Innovation Solution
A stable pharmaceutical composition comprising a bispecific single chain antibody construct, sulfobutylether-β-cyclodextrin sodium salt, and a buffer, optimized with excipients like sucrose and polysorbate 80, to reduce protein aggregation and enhance colloidal stability, thereby preventing loss-of-function and adverse immunogenic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If proteins are manufactured with high purity through commercial scale purification processes, then purity is improved, but proteins remain marginally stable and highly susceptible to degradation
Solution Approach 1:
Beta-cyclodextrin acts as a stabilizing agent that binds to hydrophobic regions of the antibody construct, preventing aggregation and degradation. The cyclodextrin molecule serves as an intermediary between the protein and the aqueous environment, reducing unwanted interactions and maintaining colloidal stability throughout the shelf life of the product.
2Manufacturing precision
If protein aggregation is removed through elaborate purification steps in downstream processing, then aggregation is reduced, but product yield decreases substantially
Solution Approach 1:
The formulation includes beta-cyclodextrin from the outset to prevent aggregation during storage and handling, rather than requiring subsequent purification steps to remove aggregates. This preliminary stabilization action maintains product integrity throughout the supply chain, eliminating the need for yield-reducing polishing steps.
3Reliability
If proteins are stabilized by modifying their primary structure through genetic engineering, then stability is improved, but functionality may be impaired and immunogenicity increased
Solution Approach 1:
Instead of modifying the protein's primary structure, the invention changes the formulation parameters by adding beta-cyclodextrin. This external stabilization approach maintains the natural amino acid sequence and structure of the antibody construct, preserving its biological activity and minimizing immunogenicity while achieving enhanced stability.
4Reliability
If protein aggregation occurs during refolding, purification, sterilization, shipping, and storage processes, then biological activity is impaired, but these processes are necessary for product manufacturing and distribution
Solution Approach 1:
The formulation incorporates beta-cyclodextrin as a protective agent that cushions the antibody construct against aggregation during stressful processes such as refolding, purification, sterilization, shipping, and storage. This prior protection allows necessary manufacturing and distribution processes to proceed without compromising product integrity or biological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively stabilizes the bispecific single chain antibody construct, reducing protein aggregation and maintaining stability under various stress conditions, including thermal and surface-induced stress, thereby ensuring the biological activity and safety of the therapeutic protein.
Implementation Method 1
a stable pharmaceutical composition comprising a bispecific single chain antibody construct, sulfobutylether-β-cyclodextrin sodium salt, and a buffer, optimized with excipients like sucrose and polysorbate 80, to reduce protein aggregation and enhance colloidal stability
Data Source
Figure 1
Figure 2A~2B
Figure 2C~3
AI summary
The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.